• Earlier in June 2026, Wolfe Research initiated coverage on Avantor, Inc. with an Underperform rating, citing several years of revenue and margin pressure, competitive share losses in its VWR distribution business, and concerns over the coherence of its product strategy.
• The coverage also highlighted that Avantor’s core operations are underperforming, with flat sales projected, weaker profitability, and a possible reliance on acquisitions to reignite growth, raising questions about the company’s longer-term business direction.
• We’ll now examine how Wolfe Research’s concerns about Avantor’s growth, margins, and competitive position may reshape the company’s investment narrative.

Find 45 companies with promising cash flow potential yet trading below their fair value.

Avantor Investment Narrative Recap

To own Avantor, you need to believe its broad lab and bioprocessing portfolio can translate into steadier growth and better margins despite recent setbacks. Wolfe Research’s Underperform call, focused on flat sales, compressed margins, and competitive pressure in VWR distribution, directly challenges that belief and reinforces the key near term risk: further profitability erosion if pricing and share losses persist. The short term catalyst remains any clear evidence of core business stabilization, which this report does not materially support.

In this context, Avantor’s Q1 2026 results are particularly relevant: sales were flat at US$1,581.4 million, while net income fell to US$43.3 million from US$64.5 million a year earlier. That pattern of stagnant revenue and weaker earnings lines up with Wolfe Research’s concern about shrinking real revenue and margin pressure, and may prompt investors to reassess how quickly, and from where, any improvement in Avantor’s earnings power could realistically emerge.

Yet behind the headline rating, a key issue investors should be aware of is how sustained margin compression could interact with...

Avantor’s narrative projects $6.9 billion revenue and $603.4 million earnings by 2029.

Uncover how Avantor's forecasts yield a $9.92 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Before this downgrade, the most cautious analysts were already assuming only about 1.3% annual revenue growth and a US$425.0 million profit by 2029, so Wolfe’s concerns about lab automation and weaker margins may push that already pessimistic path even lower, and you should know there is real disagreement about how tough Avantor’s future could be.

Explore 2 other fair value estimates on Avantor - why the stock might be worth as much as 52% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Avantor research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Avantor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Avantor's overall financial health at a glance.

No Opportunity In Avantor?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.